1 Min Read
Dec 30 (Reuters) - Incyte Corp
* Incyte announces first patient treated in pivotal clinical trial program for ruxolitinib (Jakafi) in graft-versus-host disease Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.